Grifols | GRFS - Equity Capital And Reserves


Grifols reported EUR6.21B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Arca Biopharma USD 1.11B 627.83M Jun/2026
aTyr Pharma USD 48.79M 9.15M Jun/2026
Bio Path USD -8.49M 482K Mar/2026
Brainstorm Cell Therapeutics USD -11.6M 588K Jun/2026
Capricor Therapeutics USD 246.22M 32.48M Jun/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Grifols EUR 6.21B 133.12M Dec/2025
Immunic USD 151.23M 157.91M Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
TherapeuticsMD USD 27.67M 990K Jun/2024